The global D-dimer testing market was valued at approximately US$ 1.9
Bn in 2016 is projected to register cumulative annual growth rate
(CAGR) of over 4.0% from 2017 to 2025, according to a new report
published by Transparency Market Research (TMR) titled “D-dimer
Testing Market – Global Industry Analysis, Size, Share, Growth,
Trends, and Forecast, 2017–2025”. The report suggests that surge
in incidences of deep vein thrombosis and pulmonary embolismis boost
the demand of D-dimer testing in the coming years (2017 to 2025). The
North America and Europe are projected to dominate the global D-dimer
testing market in the coming years owing to higher adoption and
awareness regarding the association between CVD risks and D-dimer
tests for exclusion of DVT, PE and DIC. Asia-Pacific, LATAM, and MEA
demonstrate slow evolution, with a huge potential for market growth.
Asia Pacific D-dimer testing market is expected to witness a CAGR of
around 5.0% from 2017 to 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2398
According to the CDC, about 900,000 people could be affected in the
U.S. each year by deep vein thrombosis. It is suggested that 60,000
to 100,000 people in the U.S. die due to deep vein thrombosis.
Clotting disorders occur when the body is unable to produce clotting
factors to stop bleeding. Deep vein thrombosis is one of the clotting
disorders, wherein there is formation of blood clot within the deep
vein, commonly in the legs. This ever-increasing burden of blood
clotting disorders is expected to drive the market during the
forecast period. Additionally, in several developed countries,
self-testing of blood by patients at home is popular. It provides
accurate and quick results, leading to the growth of the global
d-dimer testing market during the forecast period.
In terms of accurate quantitative estimation of D-dimer,
laboratory-based analysis is a robust technique as compared to
point-of-care test. Moreover, laboratory-based test can be paramount
in not only identifying individuals who are at a risk of first
thrombotic event, but also detecting the chances of having a
recurrent VTE. Overall, the drawbacks associated with laboratory test
include need for adequate space to set up and high response time (40
minutes to 50 minutes) as compared to POC tests (10 minutes to 15
minutes). The laboratory test segment has been sub-segmented into
coagulation analyzers and clinical chemistry analyzers. Clinical
chemistry analyzers are commonly used to determine D-dimer level in
blood serum in a laboratory setup. Compared to coagulation analyzers,
demand for clinical chemistry analyzers is high due to low cost of
test. Technological advancements have contributed significantly in
reducing the unit cost associated with D-dimer tests at laboratories
and POCs. The advent of sensitive D-dimer assays that are used on
automated coagulation analyzers has completely revolutionized the
market dynamics in the past few years. Kits used in coagulation
analyzers are highly specific to the device/manufacturer and are
expensive as compared to clinical chemistry analyzers.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2398
On the basis of applications, the global D-dimer testing market has
been segmented into: deep vein thrombosis (DVT), pulmonary embolism
(PE), disseminated intravascular coagulation (DIC) and others.
According to the Society of Interventional Radiology (U.S.), about
600,000 new cases of DVT are diagnosed in the U.S. each year, while
the National Health Service (NHS) records about 1 person in 1,000
with DVT in the U.K. each year. The number of D-dimer tests for DVT
application were around 58 million in 2016 and are expected to reach
around 86 million in 2025. Pulmonary embolism is difficult to detect
based on clinical symptoms and therefore demanded the use of fully
automated coagulation analyzers to run tests based on multiple
methods with increased safety, precision, and accuracy compared with
manual methods. Diagnosis of DIC is difficult because clinical
manifestations are not uniform and there is no consensus regarding
appropriate tests for laboratory diagnosis. Despite the drawbacks,
most clinicians rely on D-dimer test results to indicate the presence
or absence of DIC. In the past few years, rapid D-dimer assays with
clinical performance are at par with conventional ELISA that has
become widely available for exclusion of DIC.
Geographically, the D-dimer testing market has been segmented into
five major regions: North America, Europe, Asia Pacific, Latin
America, and Middle East and Africa. North America leads the global
D-dimer testing market valued at USD 782.8 million in 2016 owing to
higher adoption and awareness regarding the association between CVD
risks and D-dimer tests for exclusion of DVT, PE and DIC. In terms of
volume, the number of D-dimer tests in Europe stood at 48 million in
2016 and is expected to reach 67.7 million 2025. The North America
region is expected to maintain its leadership position in terms of
revenue by end of the forecast period due to the large and
ever-increasing addressable patient population base. Europe is the
largest market in 2016 in term of volume due to extensive research
activities and large number of screening programs by health care
institutes.
Key Players such as Abbott Laboratories, Siemens Healthineers, F.
Hoffmann-La Roche Ltd., and Beckman Coulter (Danaher Corporation) are
Likely to Continue to Lead the Global D-dimer Testing Market.
Report Overview @
https://www.transparencymarketresearch.com/d-dimer-market.html
The global D-dimer testing market is highly fragmented in terms of
number of players in the market providing instruments, kits, and
reagents. The key players contributing to the growth of the global
D-dimer testing market include Abbott Laboratories, Beckman Coulter,
Inc., Bio/Data Corporation, Becton, Dickinson and Company, Grifols,
S.A., F. Hoffman-La Roche Ltd., Helena Biosciences, Siemens
Healthcare, Sysmex Corporation, and Thermo Fisher Scientific.
Expansion of product portfolio through mergers and acquisitions is a
key strategy followed by many global player. For instance, on October
3, 2017, Abbott Laboratories announced the acquisition of Alere Inc.,
a provider of diagnostic devices and services, for nearly US$ 5,300.0
Mn. Through this acquisition, the company aims to expand its product
portfolio in the in-vitro diagnostics sector, thereby complementing
its leading position in the global market.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment